A breakthrough in trade talks with the U.S. might win Ishiba a reprieve, but so far there's been scant sign of progress in negotiating away the threat of higher tariffs on Japan's exports to the U.S.

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Agilysys reported quarterly earnings of $33 cents per share which missed the analyst consensus estimate of 36 cents per share. The company reported quarterly sales of $76.70 million which beat the ...